Anti-fungal drug discovery: using its patented MutantBankT technology, F2G is able to identify novel molecular targets - the first step to...
Aldezon is a start-up drug discovery business founded by Prof David Garrod (University of Manchester) and Dr Clive Robinson (St Mary's...
This spin-out company was formed in July 1999 as a joint venture between the University Of Manchester and Dr. Richard Walmsley, an expert in...
Motac provides services to clients in the pharmaceutical and biotechnology industry to aid the discovery and development of diagnostics and...
Conformetrix offers a new platform technology that, for the first time, can rapidly determine highly accurate and biologically-relevant...
NeuTec Pharma is a biopharmaceutical company which evolved from the Infectious Diseases Research Unit at the University of Manchester. Neu...
Oncoprobe Ltd was formed in 1999 to commercialise a unique technology that enables bespoke cancer treatment by determining the...
Contract molecular biology services: customised in situ Hybridisation (ISH) services for the drug development industry. ISH is an extremely...
Wound-healing therapies - development of pharmaceutical products to prevent scarring and to accelerate wound healing, for rapid repair and...
Senexis was established in 2002 with ?1.4m seed funding from BTG and Catalyst BioMedica to develop drug candidates for Alzheimer's...
ViBio Ltd is focused on the development and commercialisation of the next generation of highly accurate prognostic tests for cervical cancer....
A Cardiff-based spin-out from the Universities of Cardiff and Manchester that aims to develop selective compounds for therapeutic use in...
